To reliably detect early stages of lung cancer, it is essential to evaluate the effectiveness of the TM panel (CA-62, CEA and CYFRA 21-1) or CA-62 in specific clinical applications, such as a pilot screening program for patients in high-risk group (age over 50, chain smokers). The gene discussed is CEACAM5; the disease is lung cancer.